Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections
Abstract Background The Infectious Diseases Society of America is committed to providing
up-to-date guidance on the treatment of antimicrobial-resistant infections. This guidance …
up-to-date guidance on the treatment of antimicrobial-resistant infections. This guidance …
Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa
Multidrug-resistant (MDR) and extensively drug-resistant (XDR) Pseudomonas aeruginosa
isolates are frequent causes of serious nosocomial infections that may compromise the …
isolates are frequent causes of serious nosocomial infections that may compromise the …
Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study
Summary Background Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is a global
threat, but the distribution and clinical significance of carbapenemases are unclear. The aim …
threat, but the distribution and clinical significance of carbapenemases are unclear. The aim …
Carbapenemase-producing Pseudomonas aeruginosa –an emerging challenge
FC Tenover, DP Nicolau, CM Gill - Emerging microbes & infections, 2022 - Taylor & Francis
Carbapenem-resistant Pseudomonas aeruginosa (CR-PA) is a major healthcare-associated
pathogen worldwide. In the United States, 10–30% of P. aeruginosa isolates are …
pathogen worldwide. In the United States, 10–30% of P. aeruginosa isolates are …
Treatment of carbapenem-resistant Pseudomonas aeruginosa infections: a case for cefiderocol
ABSTRACT Introduction Carbapenem-resistant (CR) Pseudomonas aeruginosa infections
constitute a serious clinical threat globally. Patients are often critically ill and/or …
constitute a serious clinical threat globally. Patients are often critically ill and/or …
The potential of bacteriophage-antibiotic combination therapy in treating infections with multidrug-resistant bacteria
The growing threat of antibiotic resistance is a significant global health challenge that has
intensified in recent years. The burden of antibiotic resistance on public health is augmented …
intensified in recent years. The burden of antibiotic resistance on public health is augmented …
ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics
The rise of antibiotic resistance and a dwindling antimicrobial pipeline have been
recognized as emerging threats to public health. The ESKAPE pathogens—Enterococcus …
recognized as emerging threats to public health. The ESKAPE pathogens—Enterococcus …
Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients
F Barbier, S Hraiech, S Kernéis, N Veluppillai… - Annals of Intensive …, 2023 - Springer
Background Healthcare-associated infections involving Gram-negative bacteria (GNB) with
difficult-to-treat resistance (DTR) phenotype are associated with impaired patient-centered …
difficult-to-treat resistance (DTR) phenotype are associated with impaired patient-centered …
Incidence of ESBLs and carbapenemases among Enterobacterales and carbapenemases in Pseudomonas aeruginosa isolates collected globally: results from …
AC Gales, G Stone, DF Sahm… - Journal of Antimicrobial …, 2023 - academic.oup.com
Objectives To assess the global and regional distribution of ESBLs in Enterobacterales and
carbapenemases in Enterobacterales and Pseudomonas aeruginosa. Methods …
carbapenemases in Enterobacterales and Pseudomonas aeruginosa. Methods …
Cefiderocol treatment for patients with multidrug-and carbapenem-resistant Pseudomonas aeruginosa infections in the compassionate use program
Cefiderocol is an option for infections caused by multidrug-resistant Pseudomonas
aeruginosa, but its in vitro activity against these isolates and its clinical effectiveness for …
aeruginosa, but its in vitro activity against these isolates and its clinical effectiveness for …